# Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

> **NCT02107898** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 216 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Placebo (for alirocumab)
- **DRUG:** Alirocumab
- **DRUG:** Lipid-Modifying Therapy (LMT)

## Key facts

- **NCT ID:** NCT02107898
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-09
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2016-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107898, "Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02107898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*